Compare ENHA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENHA | FDMT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.1M | 695.3M |
| IPO Year | 2025 | 2019 |
| Metric | ENHA | FDMT |
|---|---|---|
| Price | $1.49 | $12.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $4.00 | ★ $28.18 |
| AVG Volume (30 Days) | 821.4K | ★ 909.8K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $168.06 | $56.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $1.37 | $6.96 |
| 52 Week High | $4.60 | $16.93 |
| Indicator | ENHA | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 36.78 |
| Support Level | N/A | $8.68 |
| Resistance Level | $1.66 | $14.00 |
| Average True Range (ATR) | 0.10 | 0.95 |
| MACD | 0.03 | -0.29 |
| Stochastic Oscillator | 44.63 | 6.87 |
Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).